Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial

Detalles Bibliográficos
Autores principales: De Angelis, Claudia, Ignatiadis, Michail, Piccart-Gebhart, Martine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Editorial Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723614/
https://www.ncbi.nlm.nih.gov/pubmed/33313083
http://dx.doi.org/10.21037/atm-20-3216
_version_ 1783620377975455744
author De Angelis, Claudia
Ignatiadis, Michail
Piccart-Gebhart, Martine
author_facet De Angelis, Claudia
Ignatiadis, Michail
Piccart-Gebhart, Martine
author_sort De Angelis, Claudia
collection PubMed
description
format Online
Article
Text
id pubmed-7723614
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-77236142020-12-10 Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial De Angelis, Claudia Ignatiadis, Michail Piccart-Gebhart, Martine Ann Transl Med Editorial Commentary AME Publishing Company 2020-11 /pmc/articles/PMC7723614/ /pubmed/33313083 http://dx.doi.org/10.21037/atm-20-3216 Text en 2020 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Editorial Commentary
De Angelis, Claudia
Ignatiadis, Michail
Piccart-Gebhart, Martine
Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
title Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
title_full Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
title_fullStr Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
title_full_unstemmed Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
title_short Cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) versus chemotherapy in luminal B early breast cancer: lessons from the CORALLEEN trial
title_sort cyclin-dependent kinases 4 and 6 inhibitors (cdk4/6i) versus chemotherapy in luminal b early breast cancer: lessons from the coralleen trial
topic Editorial Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7723614/
https://www.ncbi.nlm.nih.gov/pubmed/33313083
http://dx.doi.org/10.21037/atm-20-3216
work_keys_str_mv AT deangelisclaudia cyclindependentkinases4and6inhibitorscdk46iversuschemotherapyinluminalbearlybreastcancerlessonsfromthecoralleentrial
AT ignatiadismichail cyclindependentkinases4and6inhibitorscdk46iversuschemotherapyinluminalbearlybreastcancerlessonsfromthecoralleentrial
AT piccartgebhartmartine cyclindependentkinases4and6inhibitorscdk46iversuschemotherapyinluminalbearlybreastcancerlessonsfromthecoralleentrial

Ejemplares similares